RT Journal
A1 McIntyre RS, Jerrell JM
T1 ANtipsychotic agents and cardiometabolic morbidity in youth—reply
JF Archives of Pediatrics & Adolescent Medicine
JO Archives of Pediatrics & Adolescent Medicine
YR 2009
FD April 6
VO 163
IS 4
SP 394
OP 395
DO 10.1001/archpediatrics.2009.29
UL http://dx.doi.org/10.1001/archpediatrics.2009.29
AB 
We appreciate the comments from Drs Kruszewski and Paczynski. We share their general concern regarding the cardiometabolic hazards posed by the use of SGAs in young populations. This concern provided the impetus for us to conduct the analysis and present our findings. During the past decade, several SGAs have been introduced, widely disseminated, and highly promoted (perhaps through “aggressive off-label marketing”) as treatment options for disparate emotional, cognitive, and behavioral therapeutic targets. It is our view that SGAs provide unequivocal efficacy and, as a class of drugs, are an important adjunct to the armamentarium of treatment options available to practitioners. However, results from pragmatic trials in adult and pediatric populations along with clinical experience have underscored the finding that many, but not all, SGAs are associated with significant metabolic risks. This observation has reduced the early therapeutic euphoria that accompanied the initial use of these drugs.